Disclosures for "Randomized Controlled Trial of Intravenous Immunoblobulin for Autoimmune Postural Tachycardia Syndrome (iSTAND)"
-
Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for antag. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Autonomic Neuroscience (Elsevier). The institution of Dr. Vernino has received research support from Grifols. The institution of Dr. Vernino has received research support from Dysautonomia International. The institution of Dr. Vernino has received research support from BioHaven. The institution of Dr. Vernino has received research support from Takeda. The institution of Dr. Vernino has received research support from NIH/NHLBI. Dr. Vernino has received personal compensation in the range of $10,000-$49,999 for serving as a Content Expert Consultant with Office of Inspector General for Medicare. Dr. Vernino has a non-compensated relationship as a Board of Directors with American Autonomic Society that is relevant to AAN interests or activities.
-
Steve Hopkins, 5003 has received personal compensation in the range of $0-$499 for serving as a Consultant for Theravance Bio Pharma .
-
The institution of Dr. Bryarly has received research support from Theravance.
-
Dr. Hernandez has nothing to disclose.
-
Dr. Salter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association.